JP2008154589A5 - - Google Patents

Download PDF

Info

Publication number
JP2008154589A5
JP2008154589A5 JP2008000091A JP2008000091A JP2008154589A5 JP 2008154589 A5 JP2008154589 A5 JP 2008154589A5 JP 2008000091 A JP2008000091 A JP 2008000091A JP 2008000091 A JP2008000091 A JP 2008000091A JP 2008154589 A5 JP2008154589 A5 JP 2008154589A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
cancer
nmb
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008000091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008154589A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2008154589A publication Critical patent/JP2008154589A/ja
Publication of JP2008154589A5 publication Critical patent/JP2008154589A5/ja
Pending legal-status Critical Current

Links

JP2008000091A 2000-12-08 2008-01-04 結節性硬化症複合体関連障害の検出法および処置法 Pending JP2008154589A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25426800P 2000-12-08 2000-12-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2002548191A Division JP2005516579A (ja) 2000-12-08 2001-12-10 障害に関連する結節硬化複合症の検出法および処置法

Publications (2)

Publication Number Publication Date
JP2008154589A JP2008154589A (ja) 2008-07-10
JP2008154589A5 true JP2008154589A5 (https=) 2009-05-07

Family

ID=22963608

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002548191A Pending JP2005516579A (ja) 2000-12-08 2001-12-10 障害に関連する結節硬化複合症の検出法および処置法
JP2008000091A Pending JP2008154589A (ja) 2000-12-08 2008-01-04 結節性硬化症複合体関連障害の検出法および処置法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002548191A Pending JP2005516579A (ja) 2000-12-08 2001-12-10 障害に関連する結節硬化複合症の検出法および処置法

Country Status (9)

Country Link
US (5) US20030124534A1 (https=)
EP (1) EP1385993B8 (https=)
JP (2) JP2005516579A (https=)
AT (1) ATE506075T1 (https=)
AU (1) AU2002226079A1 (https=)
CA (1) CA2431861A1 (https=)
DE (1) DE60144493D1 (https=)
DK (1) DK1385993T3 (https=)
WO (1) WO2002046475A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211488A1 (en) 2002-05-07 2003-11-13 Northwestern University Nanoparticle probs with Raman spectrocopic fingerprints for analyte detection
CA2439440A1 (en) * 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
AU2005322410B2 (en) 2004-11-30 2011-11-10 Amgen Fremont Inc. Antibodies directed to GPNMB and uses thereof
US20120252877A1 (en) * 2009-08-14 2012-10-04 Theramind Research, Llc Methods and compositions for treatment of tuberous sclerosis complex
WO2014137978A1 (en) 2013-03-04 2014-09-12 The Brigham And Women's Hospital, Inc. Treatment of lymphangioleiomyomatosis
US20160129030A1 (en) * 2013-06-14 2016-05-12 The Brigham And Women's Hospital, Inc. Treatment of mtor hyperactive related diseases and disorders
WO2023178250A1 (en) * 2022-03-17 2023-09-21 SpringWorks Therapeutics Inc. Treatment of tuberous sclerosis with mirdametinib

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
JP3715314B2 (ja) * 1993-12-24 2005-11-09 ユニバーシティ オブ ウェールズ カレッジ オブ メディスン 結節硬化症２遺伝子及びその利用
US5871697A (en) * 1995-10-24 1999-02-16 Curagen Corporation Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
EP0870057B1 (en) * 1995-11-16 2003-09-24 The Baylor College Of Medicine Method for identifying metastatic sequences
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
YU72901A (sh) 1999-04-02 2004-07-15 Corixa Corporation Preparati za primenu u terapiji i dijagnozi raka pluća
US6620615B1 (en) * 1999-04-23 2003-09-16 Curagen Corporation G-protein coupled receptor—encoding nucleic acids
AU2001273150A1 (en) 2000-07-20 2002-02-05 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002062947A2 (en) 2000-10-20 2002-08-15 University Of Medicine And Dentistry New Jersey Medical School Hematopoietic growth factor inducible neurokinin-1 gene
WO2002086122A2 (en) 2001-03-14 2002-10-31 Hybrigenics Protein-protein interactions in adipocytes
CA2444691A1 (en) 2001-04-18 2002-10-31 Protein Design Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer

Similar Documents

Publication Publication Date Title
JP2008154589A5 (https=)
JP2012046518A5 (https=)
JP2014530215A5 (https=)
JP2019501204A5 (https=)
JP2016187356A5 (https=)
JP2009505676A5 (https=)
HRP20211710T1 (hr) Konjugacija specifična za mjesto spajanja lijekova za povezivanje s protutijelima i konjugati protutijela u lijeku koji nastaje kao rezultat
HRP20180507T1 (hr) Identifikacija antigena povezanih s tumorom za dijagnozu i terapiju
JP2020536109A5 (https=)
EA201290062A1 (ru) Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений
EA201190116A1 (ru) Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1
JP2014502955A5 (https=)
UA116772C2 (uk) Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47
MX2009012967A (es) Polipeptidos, dominios variables de anticuerpo y antagonistas.
JP2010535713A5 (https=)
MX2009012968A (es) Polipeptidos, dominios variables de anticuerpo y antagonistas.
PL2097453T3 (pl) Przeciwciała monoklonalne przeciw ludzkiemu receptorowi hormonu anty-Mullerowskiego typu II (AMHR-II)
JP2015529641A5 (https=)
JP2018515137A5 (https=)
JP2015512412A5 (https=)
JP2016508973A5 (https=)
JP2012102122A5 (https=)
JP2013533269A5 (https=)
RU2014142057A (ru) Комплексная терапия
JP2014507435A5 (https=)